The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Small molecule compounds targeting the p53 pathway: are we finally making progress?
Abstract
Loss of function of p53, either through mutations in the gene or through mutations to other members of the pathway that inactivate wild-type p53, remains a critically important aspect of human cancer development. As such, p53 remains the most commonly mutated gene in human cancer. For these reasons, pharmacologic activation of the p53 pathway has been a highly sought after, yet unachieved goal in developmental therapeutics. Recently progress has been made not only in the discovery of small molecules that target wild-type and mutant p53, but also in the initiation and completion of the first in-human clinical trials for several of these drugs. Here, we review the current literature of drugs that target wild-type and mutant p53 with a focus on small-molecule type compounds. We discuss common means of drug discovery and group them according to their common mechanisms of action. Lastly, we review the current status of the various drugs in the development process and identify newer areas of p53 tumor biology that may prove therapeutically useful.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a number of small molecule compounds, peptide or antibody drugs targeting p53 mutants have been developed to recover the native conformation or normal function of the p53 protein.381–385”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [381]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Cancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452 · cited 2×
“metabolism of cancer cells is altered in ways that provide a selective advantage for tumor progression and tumor maintenance [94, 95].”
BackgroundStructure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“Restoration of p53 function lead to apoptosis in lymphomas and senescence in sarcomas [12].”
Backgroundp53 Regulates Mitochondrial Respiration
Matoba, S., Kang, J.-G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F., & Hwang, P. M. (2006) · Science · doi:10.1126/science.1126863 · Cited by 1,650
p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling
Budanov, A. V., & Karin, M. (2008) · Cell · doi:10.1016/j.cell.2008.06.028 · Cited by 1,326
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells
Maddocks, O. D. K., Berkers, C. R., Mason, S. M., Zheng, L., Blyth, K., Gottlieb, E., & Vousden, K. H. (2013) · Nature · doi:10.1038/nature11743 · Cited by 1,007
Vousden, K. H., & Ryan, K. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2715 · Cited by 959 · cited 1×
“In general p53 functions to slow down glycolysis and speed up oxidative phosphorylation in essence opposing the Warburg effect [108, 109].”
BackgroundAwakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 2×
“hand, structural mutations (such as R175H and R249S) have a significant effect on protein folding causing destabilization of the protein structure [37, 82].”
BackgroundSmall-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., Stuckey, J., Krajewski, K., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm051122a · Cited by 702
Structure-based design of potent non-peptide MDM2 inhibitors
Ding, K., Lu, Y., Nikolovska-Coleska, Z., Qiu, S., Ding, Y., Gao, W., Stuckey, J., Krajewski, K., Roller, P. P., Tomita, Y., et al. (2005) · Journal of the American Chemical Society · doi:10.1021/ja051147z · Cited by 657
Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., & Levine, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4149 · Cited by 633
Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 1×
“(2) Lessons learned from murine models of cancer indicate that restoring the function of wild-type p53 in tumors is highly therapeutic and in some instances curative [11–13].”
BackgroundPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
The p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450
Choudhury, A. R., Ju, Z., Djojosubroto, M. W., Schienke, A., Lechel, A., Schaetzlein, S., Jiang, H., Stepczynska, A., Wang, C., Buer, J., et al. (2007) · Nature Genetics · doi:10.1038/ng1937 · Cited by 426 · cited 1×
“For example, mice lacking either PUMA, NOXA or p21 which are downstream of p53 in mediating both apoptosis, and cell cycle arrest fail to develop spontaneous tumors [97, 98].”
BackgroundLehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 4×
“The increase in p53 activity did not appear to correlate with p53 mutational status and further assessment of APR-246 needs to be made to assess its ability as a mutant reactivator [87].”
BackgroundInfluentialKeeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4
Marine, J.-C., Francoz, S., Maetens, M., Wahl, G., Toledo, F., & Lozano, G. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401912 · Cited by 352
Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5835-5843.2004 · Cited by 310 · cited 8×
“Alternatively overexpression of the negative regulator MDMX can result in a similar effect (impaired p53 signaling) [21].”
BackgroundInfluentialMirzayans, R., Andrais, B., Scott, A., & Murray, D. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/170325 · Cited by 257
Blagosklonny, M. V. (2012) · Aging · doi:10.18632/aging.100443 · Cited by 251
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization
Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203789109 · Cited by 230
Tumor suppression and normal aging in mice with constitutively high p53 activity
Mendrysa, S. M., O'Leary, K. A., McElwee, M. K., Michalowski, J., Eisenman, R. N., Powell, D. A., & Perry, M. E. (2006) · Genes & Development · doi:10.1101/gad.1378506 · Cited by 210 · cited 1×
“or genetically) leads to an increase in p53 activity [38–41].”
BackgroundIdentification and Characterization of the First Small Molecule Inhibitor of MDMX
Reed, D., Shen, Y., Shelat, A. A., Arnold, L. A., Ferreira, A. M., Zhu, F., Mills, N., Smithson, D. C., Regni, C. A., Bashford, D., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.056747 · Cited by 198 · cited 2×
“Table 1 Compounds and small molecules that target wild-type and mutant p53 Molecule/compound Mechanism of action Target Stage of development Activate wild-type p53 Nutlins RG7112 (RO5045337) Inhibits p53-MDM2 binding MDM2 Phase I clinical trial (NCT01164033, NCT01143740, NCT00623870 and NCT00559533) [48] Benzodiazepin…”
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z.-G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102309108 · Cited by 193
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint
Kleiblova, P., Shaltiel, I. A., Benada, J., Ševčík, J., Pecháčková, S., Pohlreich, P., Voest, E. E., Dundr, P., Bartek, J., Kleibl, Z., et al. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201210031 · Cited by 170
Hdmx modulates the outcome of p53 activation in human tumor cells
Wade, M., Wong, E. T., Tang, M., Stommel, J. M., & Wahl, G. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605405200 · Cited by 163
Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2
de Graaf, P., Little, N. A., Ramos, Y. F. M., Meulmeester, E., Letteboer, S. J. F., & Jochemsen, A. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m213034200 · Cited by 143
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0337 · Cited by 78
Matthew, E. M., Hart, L. S., Astrinidis, A., Navaraj, A., Dolloff, N. G., Dicker, D. T., Henske, E. P., & El-Deiry, W. S. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10800 · Cited by 67
Tabernero, J., Dirix, L., Schöffski, P., Cervantes, A., Lopez-Martin, J. A., Capdevila, J., van Beijsterveldt, L., Platero, S., Hall, B., Yuan, Z., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1101 · Cited by 64
Chargari, C., Leteur, C., Angevin, E., Bashir, T., Schoentjes, B., Arts, J., Janicot, M., Bourhis, J., & Deutsch, E. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.08.011 · Cited by 54 · cited 3×
“JNJ-26854165 (Serdemetan) Inhibits p53-MDM2 binding MDM2 Phase I clinical trial (NCT00676910) [58, 60]”
BackgroundInitial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program
Smith, M. A., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., Maris, J. M., Keir, S. T., Morton, C. L., Reynolds, C. P., Kang, M. H., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.23319 · Cited by 26 · cited 1×
“Other pre-clinical studies have also found activity in both wild-type and mutant p53 tumors indicating that the mechanism involves both p53 dependent and independent functions [59].”
Background
Research works printed but not linked: 73
- Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493–502 · DOI · Paper page
- Joensuu H (2012) Adjuvant treatment of GIST: patient selection and treatment strategies. Nat Rev Clin Oncol 9:351–358 · DOI
- Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139 · DOI · Paper page
- Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331 · DOI · Paper page
- Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 2:594–604 · DOI · Paper page
- Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275:8945–8951 · DOI · Paper page
- Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299 · DOI · Paper page
- Midgley CA, Lane DP (1997) p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 15:1179–1189 · DOI · Paper page
- Li D, Marchenko ND, Schulz R et al (2011) Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Molecular cancer research : MCR 9:577–588 · DOI · Paper page
- Sigal A, Rotter V (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60:6788–6793
- Adorno M, Cordenonsi M, Montagner M et al (2009) A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137:87–98 · DOI · Paper page
- Dittmer D, Pati S, Zambetti G et al (1993) Gain of function mutations in p53. Nat Genet 4:42–46 · DOI · Paper page
- Liu G, McDonnell TJ, de Oca Montes, Luna R et al (2000) High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA 97:4174–4179 · DOI · Paper page
- Sherr CJ, Weber JD (2000) The ARF/p53 pathway. Curr Opin Genet Dev 10:94–99 · DOI · Paper page
- Lane DP, Cheok CF, Lain S (2010) p53-based cancer therapy. Cold Spring Harb Perspect Biol 2:a001222
- Bouchet BP, Caron de Fromentel C, Puisieux A, Galmarini CM (2006) p53 as a target for anti-cancer drug development. Crit Rev Oncol/Hematol 58:190–207 · DOI
- Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105:10360–10365 · DOI · Paper page
- Joerger AC, Ang HC, Fersht AR (2006) Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 103:15056–15061 · DOI · Paper page
- Wassman CD, Baronio R, Demir O et al (2013) Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53. Nat Commun 4:1407 · DOI · Paper page
- Freed-Pastor WA, Prives C (2012) Mutant p53: one name, many proteins. Genes Dev 26:1268–1286 · DOI · Paper page
- Wang W, Kim SH, El-Deiry WS (2006) Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 103:11003–11008 · DOI
- Kravchenko JE, Ilyinskaya GV, Komarov PG et al (2008) Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 105:6302–6307 · DOI · Paper page
- Yu X, Vazquez A, Levine AJ, Carpizo DR (2012) Allele-specific p53 mutant reactivation. Cancer Cell 21:614–625 · DOI · Paper page
- Shoemaker RH (2006) The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 6:813–823 · DOI · Paper page
- Ikediobi ON, Davies H, Bignell G et al (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5:2606–2612 · DOI · Paper page
- Peltonen K, Colis L, Liu H et al (2010) Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One 5:e12996 · DOI
- Chene P (2004) Inhibition of the p53-MDM2 interaction: targeting a protein–protein interface. Mol Cancer Res 2:20–28 · DOI
- Chen L, Agrawal S, Zhou W, Zhang R, Chen J (1998) Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci USA 95:195–200 · DOI · Paper page
- Wasylyk C, Salvi R, Argentini M et al (1999) p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 18:1921–1934 · DOI
- Tortora G, Caputo R, Damiano V et al (2000) A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int J Cancer 88:804–809 · DOI
- Vassilev LT, Vu BT, Graves B et al (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844–848 · DOI · Paper page
- Tovar C, Graves B, Packman K et al (2013) MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models. Cancer Res 73:2587–2597 · DOI · Paper page
- Saha MN, Qiu L, Chang H (2013) Targeting p53 by small molecules in hematological malignancies. J Hematol Oncol 6:23 · DOI
- Brown CJ, Cheok CF, Verma CS, Lane DP (2011) Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 32:53–62 · DOI
- Zou P, Zheng N, Yu Y et al (2012) Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics. J Pharm Pharm Sci 15:265–280 · DOI
- Issaeva N, Bozko P, Enge M et al (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10:1321–1328 · DOI · Paper page
- Krajewski M, Ozdowy P, D’Silva L, Rothweiler U, Holak TA (2005) NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med 11:1135–1136 author reply 1136–1137 · DOI
- Saha MN, Jiang H, Yang Y et al (2012) Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One 7:e30215 · DOI
- Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G (2010) Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 9:1847–1855 · DOI · Paper page
- Roh JL, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM (2012) The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer Lett 325:35–41 · DOI
- Wang X, Wang J, Jiang X (2011) MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. J Biol Chem 286:23725–23734 · DOI
- Vassilev LT (2005) p53 Activation by small molecules: application in oncology. J Med Chem 48:4491–4499 · DOI · Paper page
- Hu B, Gilkes DM, Chen J (2007) Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX. Cancer Res 67:8810–8817 · DOI · Paper page
- Wang H, Yan C (2011) A small-molecule p53 activator induces apoptosis through inhibiting MDMX expression in breast cancer cells. Neoplasia 13:611–619 · DOI
- Lain S, Hollick JJ, Campbell J et al (2008) Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 13:454–463 · DOI · Paper page
- Gudkov AV, Komarova EA (2003) The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 3:117–129 · DOI · Paper page
- Mendrysa SM, McElwee MK, Michalowski J, O’Leary KA, Young KM, Perry ME (2003) mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 23:462–472 · DOI · Paper page
- Canner JA, Sobo M, Ball S et al (2009) MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53. Br J Cancer 101:774–781 · DOI
- Graat HC, Carette JE, Schagen FH et al (2007) Enhanced tumor cell kill by combined treatment with a small-molecule antagonist of mouse double minute 2 and adenoviruses encoding p53. Mol Cancer Ther 6:1552–1561 · DOI
- Cheok CF, Dey A, Lane DP (2007) Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res 5:1133–1145 · DOI
- Levine AJ, Wu MC, Chang A et al (1995) The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a “gain of function” phenotype. Ann N Y Acad Sci 768:111–128 · DOI
- Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286:2507–2510 · DOI · Paper page
- Haupt S, Haupt Y (2004) Manipulation of the tumor suppressor p53 for potentiating cancer therapy. Semin Cancer Biol 14:244–252 · DOI
- Rippin TM, Bykov VJ, Freund SM, Selivanova G, Wiman KG, Fersht AR (2002) Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21:2119–2129 · DOI · Paper page
- Bykov VJ, Issaeva N, Zache N et al (2005) Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 280:30384–30391 · DOI · Paper page
- Wiman KG (2010) Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 29:4245–4252 · DOI · Paper page
- Liu X, Wilcken R, Joerger AC et al (2013) Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res 41:6034–6044 · DOI · Paper page
- Puca R, Nardinocchi L, Porru M et al (2011) Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 10:1679–1689 · DOI
- Yu Y, Kalinowski DS, Kovacevic Z et al (2009) Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem 52:5271–5294 · DOI · Paper page
- Terzian T, Suh YA, Iwakuma T et al (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22:1337–1344 · DOI · Paper page
- DeBerardinis RJ, Mancuso A, Daikhin E et al (2007) Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 104:19345–19350 · DOI · Paper page
- Michalak EM, Villunger A, Adams JM, Strasser A (2008) In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 15:1019–1029 · DOI · Paper page
- Li T, Kon N, Jiang L et al (2012) Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149:1269–1283 · DOI · Paper page
- Blagosklonny MV (2012) Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression? Aging (Albany NY) 4:450–455 · DOI
- Feng Z, Zhang H, Levine AJ, Jin S (2005) The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA 102:8204–8209 · DOI · Paper page
- Janes MR, Fruman DA (2010) Targeting TOR dependence in cancer. Oncotarget 1:69–76 · DOI
- Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH (2013) Metabolic regulation by p53 family members. Cell Metab 18:617–633 · DOI · Paper page
- Cheung EC, Athineos D, Lee P et al (2013) TIGAR is required for efficient intestinal regeneration and tumorigenesis. Dev Cell 25:463–477 · DOI · Paper page
- Gottlieb E, Vousden KH (2010) p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol 2:a001040 · DOI · Paper page
- Buzzai M, Jones RG, Amaravadi RK et al (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745–6752 · DOI · Paper page
- Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z (2010) Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 107:7455–7460 · DOI · Paper page
- Desilet N, Campbell TN, Choy FY (2010) p53-based anti-cancer therapies: an empty promise? Curr Issues Mol Biol 12:143–146
- Brooks CL, Gu W (2008) p53 Activation: a case against Sir. Cancer Cell 13:377–378 · DOI
Cited by
Pistritto, G., Trisciuoglio, D., Ceci, C., Garufi, A., & D'Orazi, G. (2016) · Aging · doi:10.18632/aging.100934 · Cited by 1,658
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 587
Metadata
- Authors
- Yu, X., Narayanan, S., Vazquez, A., & Carpizo, D. R.
- Venue
- Apoptosis
- Published
- 2014-04-23
- Volume
- 19
- Issue
- 7
- Pages
- 1055-1068
- ISSN
- 1360-8185
- 1573-675X
- Cited by
- 59
- References
- 44
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.